Athenex Stock

Athenex EV/FCF

Delisted

The EV/FCF (Enterprise Value to Free Cash Flow) of Athenex (ATNX) as of Aug 24, 2026 is -1.50. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -0.76 — a change of 96.44% (lower).

EV/FCF

-1.50

YoY

96.44%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Athenex is 2026 -1.50 . EV/FCF (Enterprise Value to Free Cash Flow) of Athenex was 2025 -0.76 . It decreases by 96.44% lower compared to the previous year.

The Athenex EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2015
0.64 USD
Jan 1, 2016
-0.38 USD
Jan 1, 2017
0.23 USD
Jan 1, 2018
0.29 USD
Jan 1, 2019
0.69 USD
Jan 1, 2020
0.33 USD
Jan 1, 2021
-0.76 USD
Jan 1, 2022
-1.50 USD
The Athenex EV/FCF history
YEAREV/FCFYoY
-1.50+96.44%
-0.76-331.16%
0.33-52.00%
0.69+140.44%
0.29+22.35%
0.23-162.19%
-0.38-158.83%
0.64-127.09%
-2.36
Access this data via the Eulerpool API

Athenex Stock analysis

What does Athenex do? Athenex Inc was founded in 2003 and is headquartered in Buffalo, New York. The company specializes in the development and marketing of innovative drugs and therapies for the treatment of cancer and other serious diseases. Athenex's business model is based on collaboration with other companies and research institutions. The company works closely with academic partners to identify and develop new technologies and active ingredients. Athenex has also entered into several collaboration agreements with major pharmaceutical companies to facilitate the marketing of its products. The company has multiple divisions: Athenex Pharmaceutical Division, Athenex Oncology Division, and Athenex Pharmaceutical Technology Division. The Athenex Pharmaceutical Division focuses on the development and marketing of drugs for the treatment of cancer and other serious illnesses. The company has several promising drug candidates in its pipeline, including Oratopo, a drug for the treatment of breast cancer, and KX-2-391, a drug for the treatment of prostate cancer. The Athenex Oncology Division focuses on the development and marketing of innovative cancer treatment methods. The company has several promising therapy approaches in its pipeline, including an immunological cancer treatment based on activating the immune system to fight cancer cells. The Athenex Pharmaceutical Technology Division utilizes advanced technologies to improve the effectiveness and tolerability of drugs, including novel drug delivery systems and innovative packaging forms. Athenex also offers a wide range of products and services for the pharmaceutical industry, including drug development and manufacturing, as well as the supply of active ingredients and excipients. Overall, Athenex has a broad and interesting business model and a promising portfolio of drug candidates and therapy approaches in its pipeline. The company has also established strong partnerships with other companies and research institutions to advance its development and marketing of drugs and therapies. Athenex is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athenex stock

EV/FCF (Enterprise Value to Free Cash Flow) of Athenex is -1.50 in 2026.

EV/FCF (Enterprise Value to Free Cash Flow) of Athenex changed from -0.76 to -1.50, representing a 96.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Athenex since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Athenex with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Athenex

All Key Metrics — Athenex